Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorKloprogge, Frank
dc.contributor.authorMwandumba, Henry C.
dc.contributor.authorKamdolozi, Mercy
dc.contributor.authorBanda, Gertrude
dc.contributor.authorShani, Doris
dc.contributor.authorCorbett, Elizabeth L.
dc.contributor.authorKontogianni, Nadia
dc.contributor.authorWard, Steve
dc.contributor.authorKhoo, Saye H.
dc.contributor.authorDavies, Geraint R.
dc.contributor.authorSloan, Derek James
dc.date.accessioned2020-08-07T12:30:02Z
dc.date.available2020-08-07T12:30:02Z
dc.date.issued2020-07
dc.identifier269485795
dc.identifier128b962a-7c3a-4715-9b3c-6b542badc76e
dc.identifier85090776471
dc.identifier000577171200011
dc.identifier.citationKloprogge , F , Mwandumba , H C , Kamdolozi , M , Banda , G , Shani , D , Corbett , E L , Kontogianni , N , Ward , S , Khoo , S H , Davies , G R & Sloan , D J 2020 , ' Longitudinal PKPD biomarkers correlate with treatment outcome in drug sensitive pulmonary tuberculosis; a population pharmacokinetic-pharmacodynamic analysis ' , Open Forum Infectious Diseases , vol. 7 , no. 7 , ofaa218 . https://doi.org/10.1093/ofid/ofaa218en
dc.identifier.issn2328-8957
dc.identifier.otherORCID: /0000-0002-7888-5449/work/78528205
dc.identifier.urihttps://hdl.handle.net/10023/20426
dc.descriptionFunding: Wellcome Trust Clinical PhD Fellowship awarded to D.S. (086757/Z/08/A). Funding for the minimum inhibitory concentration assays was provided by a grant from the British Society for Antimicrobial Chemotherapy (GA2015_036P). F.K. has conducted the research as part of his Medical Research Council fellowship (MR/P014534/1).en
dc.description.abstractBackground . This study aims to explore relationships between baseline demographic covariates, plasma antibiotic exposure, sputum bacillary load, and clinical outcome data to help improve future tuberculosis (TB) treatment response predictions. Methods . Data were available from a longitudinal cohort study in Malawian drug-sensitive TB patients on standard therapy, including steady-state plasma antibiotic exposure (154 patients), sputum bacillary load (102 patients), final outcome (95 patients), and clinical details. Population pharmacokinetic and pharmacokinetic-pharmacodynamic models were developed in the software package NONMEM. Outcome data were analyzed using univariate logistic regression and Cox proportional hazard models in R, a free software for statistical computing. Results . Higher isoniazid exposure correlated with increased bacillary killing in sputum (P < .01). Bacillary killing in sputum remained fast, with later progression to biphasic decline, in patients with higher rifampicin area under the curve (AUC)0-24 (P < .01). Serial sputum colony counting negativity at month 2 (P < .05), isoniazid CMAX (P < .05), isoniazid CMAX/minimum inhibitory concentration ([MIC] P < .01), and isoniazid AUC0-24/MIC (P < .01) correlated with treatment success but not with remaining free of TB. Slower bacillary killing (P < .05) and earlier progression to biphasic bacillary decline (P < .01) both correlate with treatment failure. Posttreatment recurrence only correlated with slower bacillary killing (P < .05). Conclusions . Patterns of early bacillary clearance matter. Static measurements such as month 2 sputum conversion and pharmacokinetic parameters such as CMAX/MIC and AUC0-24/MIC were predictive of treatment failure, but modeling of quantitative longitudinal data was required to assess the risk of recurrence. Pooled individual patient data analyses from larger datasets are needed to confirm these findings.
dc.format.extent11
dc.format.extent426315
dc.language.isoeng
dc.relation.ispartofOpen Forum Infectious Diseasesen
dc.subjectOutcomeen
dc.subjectPharmacokineticsen
dc.subjectPharmacodynamicsen
dc.subjectStandard treatmenten
dc.subjectTuberculosisen
dc.subjectRC Internal medicineen
dc.subjectRM Therapeutics. Pharmacologyen
dc.subjectNDASen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subject.lccRCen
dc.subject.lccRMen
dc.titleLongitudinal PKPD biomarkers correlate with treatment outcome in drug sensitive pulmonary tuberculosis; a population pharmacokinetic-pharmacodynamic analysisen
dc.typeJournal articleen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.contributor.institutionUniversity of St Andrews. Infection and Global Health Divisionen
dc.identifier.doi10.1093/ofid/ofaa218
dc.description.statusPeer revieweden


This item appears in the following Collection(s)

Show simple item record